Novavax

Novavax
Name	Novavax, Inc.
Type	Public
Industry	Biotechnology
Founded	1987
Headquarters	Gaithersburg, Maryland, United States
Key people	Stanley C. Erck
Products	Protein subunit vaccines
Revenue	(varies)
Employees	(varies)

Novavax Novavax, Inc. is an American biotechnology company focused on developing protein subunit vaccines for infectious diseases. Founded in the late 20th century, the company has been involved in vaccine research against influenza, respiratory syncytial virus, and severe acute respiratory syndrome coronavirus 2, interacting with institutions such as the National Institutes of Health, Coalition for Epidemic Preparedness Innovations, Operation Warp Speed, and multinational regulators including the European Medicines Agency and the U.S. Food and Drug Administration. Novavax's programs have attracted attention from public health agencies, healthcare providers, philanthropic organizations, and investors on global markets such as the NASDAQ and international procurement mechanisms like COVAX.

History

The company was established in 1987, emerging during a period of expanding biotechnology activity alongside firms like Genentech, Amgen, and Biogen. Early work included recombinant protein research and partnerships with academic laboratories at institutions such as the University of Maryland and the Johns Hopkins University. During the 2000s and 2010s Novavax pursued candidate vaccines for seasonal and pandemic influenza and engaged with regulatory bodies including the U.S. Department of Health and Human Services and the European Commission for development support. The SARS-CoV-2 pandemic propelled Novavax into global prominence after receiving funding and supply agreements from entities like BARDA, Gavi, the Vaccine Alliance, and several national ministries of health, while negotiating manufacturing deals with companies such as Serum Institute of India and Takeda Pharmaceutical Company.

Corporate structure and operations

Novavax operates as a publicly listed corporation with headquarters in Gaithersburg, Maryland, and additional facilities for development and manufacturing in locations including North Carolina, Stockholm, and strategic partnerships worldwide. Executive leadership has engaged with investors on the NASDAQ and institutional shareholders like sovereign wealth and hedge funds. The corporate governance framework includes a board of directors with experience in biotechnology and pharmaceuticals; Novavax has engaged with contract development and manufacturing organizations (CDMOs) such as Emergent BioSolutions and multinational partners like Cytiva for upstream and downstream processing equipment. The company’s operations intersect with procurement entities including national ministries of health and international bodies such as UNICEF for distribution logistics.

Vaccine development and technology

Novavax specializes in recombinant protein nanoparticle vaccine technology, producing stabilized antigenic proteins combined with saponin-based adjuvants. Central to its platform is the use of recombinant expression systems producing spike or hemagglutinin proteins, assembled into nanoparticles to elicit immune responses, paired with an adjuvant derived from the bark of Quillaja saponaria produced under trade names developed by partners. The platform has parallels with protein subunit approaches used by companies like Sanofi and academic efforts at Emory University and University of Oxford but differs from nucleic acid approaches advanced by Moderna and Pfizer. Novavax’s pipeline has included candidates for seasonal and pandemic influenza, respiratory syncytial virus, and coronavirus vaccines targeting variants characterized by groups such as the World Health Organization’s Technical Advisory Group.

Clinical trials and regulatory approvals

Novavax conducted multi-phase clinical programs across geographic sites including centers in the United States, United Kingdom, South Africa, and Mexico, enrolling thousands of participants in randomized controlled trials. Phase I/II and Phase III trials evaluated safety, immunogenicity, and efficacy endpoints against laboratory-confirmed disease, with data submitted to regulators such as the U.S. Food and Drug Administration, the European Medicines Agency, and national regulatory authorities in India and Australia. Emergency use authorizations and conditional approvals were sought and in some jurisdictions granted after review by advisory committees and pharmacovigilance bodies, informing deployment decisions by agencies including the Centers for Disease Control and Prevention and national immunization technical advisory groups.

Manufacturing and supply chain

To scale production, Novavax entered manufacturing agreements and technology transfer arrangements with global manufacturers including the Serum Institute of India, Takeda Pharmaceutical Company, and contract manufacturers in Belgium and the United States. Production required coordination of upstream expression systems, downstream purification, adjuvant supply chains, and fill-finish capacity, often relying on third-party suppliers for single-use systems and chromatography resins produced by firms such as Sartorius and Thermo Fisher Scientific. Distribution planning involved cold-chain logistics coordinated with international freight providers and procurement mechanisms like Gavi and COVAX to supply low- and middle-income countries.

Controversies and legal issues

Novavax’s development trajectory included disputes and legal actions typical of the biotechnology sector, including litigation over intellectual property, contractual disagreements with manufacturing partners, and scrutiny from regulatory inspectors during inspections of contract facilities such as those operated by Emergent BioSolutions. The company faced public debate about manufacturing delays, supply shortfalls, and liability protections negotiated with governments such as procurement contracts with the United Kingdom and European Union. Shareholder litigation and securities-related inquiries have emerged linked to timing of clinical disclosures and financial statements, reflecting interactions with regulators such as the Securities and Exchange Commission and investor advocacy groups.

Category:Biotechnology companies Category:Vaccine manufacturers Category:Pharmaceutical companies of the United States